Surprisingly, Akebia’s oral HIF-PHI drug, Vadadustat, has shown heart safety concerns in a phase III study for non-dialysis CKD-anaemic patients. Although partner Vifor isn’t impacted directly – it holds the distribution rights for dialysis centres in the US – cardiovascular issues in the non-dialysis indication could have a spillover effect on the usage of the drug in the dialysis setting. There is now uncertainty with respect to regulatory approval as well. Rival dru
07 Sep 2020
Partner Akebia’s drug hits a roadblock
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Partner Akebia’s drug hits a roadblock
- Published:
07 Sep 2020 -
Author:
Sumit Sayal -
Pages:
2
Surprisingly, Akebia’s oral HIF-PHI drug, Vadadustat, has shown heart safety concerns in a phase III study for non-dialysis CKD-anaemic patients. Although partner Vifor isn’t impacted directly – it holds the distribution rights for dialysis centres in the US – cardiovascular issues in the non-dialysis indication could have a spillover effect on the usage of the drug in the dialysis setting. There is now uncertainty with respect to regulatory approval as well. Rival dru